Menu Close

Athina (Tina) Soulis

Strategic Advisor, Neuroscience Trials Australia, Florey Institute of Neuroscience and Mental Health, The University of Melbourne

Dr Tina Soulis has over 27 years of working in the healthcare (pharmaceuticals and devices), biotechnology, academic research, clinical research and management sectors in senior roles including: CEO of a Contract Research Organization, Director of a successful ASX200 company, VP of Clinical Strategy and Development with an innovative biotechnology company and now, Founder and Director of her own clinical consultancy company. A dynamic and strategic leader, Tina has an extensive network of stakeholders all over the world and experience in many therapeutic areas across all phases on development.

Tina holds academic appointments with:
* University of Melbourne (teaching and supporting undergraduate pharmacology, Masters in Leadership in Science and Master in Commercialization in Science students)

Passionate about mentoring future industry leaders and advocating for the Australian R&D community, Tina serves on several therapeutics executive advisory boards and advisors many US-based biotechnology companies including:
- Australian Neimann Pick-Type C Disease Foundation
-National Imaging Facility
-AusBiotech ABCTag clinical trials executive committee

Tina is a regular invited speaker locally and globally on a broad range of topics on Clinical trials, Research, Innovation and Industry Collaboration.

Recently, Tina launched her own consultancy, Alithia Life Sciences, where her motivation and mission is to work with her clients to deliver efficient accomplishment of their project, add value to their programs and to ultimately enable improvement of human health and wellbeing.

Tina is also VP of Clinical Strategy and Development for Kinoxis Therapeutics Pty Ltd, an innovative NIH/NIDA backed biotechnology company developing novel therapies for unmet neurological conditions.

Being strategic advisor to Neuroscience Trials Australia (NTA), a world-leading Contract Research Organization (CRO) specializing in all aspects of (neuroscience) clinical development also keeps Tina inspired about new products being developed. Focused on delivering global standard clinical trial projects for pharmaceutical, biotechnology and device clients, this CRO aims to create value for clients. When Tina was CEO for NTA, she successfully grew the business on average 39% annually, thus forming a sustainable and world-respected organization.

Tina is one of the few Australian clinical development leaders who has successfully taken products from lab to regulatory approval.


  • –present
    Strategic Advisor and previous CEO to Neuroscience Trials Australia, The University of Melbourne


  • 1998 
    University of Melbourne , PhD in Medicine
  • Article Feed
  • Joined